Please use this identifier to cite or link to this item: http://repositorio.unifesp.br/handle/11600/42649
Title: Effect of EPI-743 on the Clinical Course of the Mitochondrial Disease Leber Hereditary Optic Neuropathy
Authors: Sadun, Alfredo A.
Chicani, Carlos Filipe [UNIFESP]
Ross-Cisneros, Fred N.
Barboni, Piero
Thoolen, Martin
Shrader, William D.
Kubis, Kenneth
Carelli, Valerio
Miller, Guy
USC Keck Sch Med
Universidade Federal de São Paulo (UNIFESP)
Univ Bologna
Edison Pharmaceut Inc
Stanford Univ
USN
Issue Date: 1-Mar-2012
Publisher: Amer Medical Assoc
Citation: Archives Of Neurology. Chicago: Amer Medical Assoc, v. 69, n. 3, p. 331-338, 2012.
Abstract: Objective: To evaluate the safety and efficacy of a new therapeutic agent, EPI-743, in Leber hereditary optic neuropathy (LHON) using standard clinical, anatomic, and functional visual outcome measures.Design: Open-label clinical trial.Setting: University medical center.Patients: Five patients with genetically confirmed LHON with acute loss of vision were consecutively enrolled and treated with the experimental therapeutic agent EPI-743 within 90 days of conversion.Intervention: During the course of the study, 5 consecutive patients received EPI-743, by mouth, 3 times daily (100-400 mg per dose).Main Outcome Measures: Treatment effect was assessed by serial measurements of anatomic and functional visual indices over 6 to 18 months, including Snellen visual acuity, retinal nerve fiber layer thickness measured by optical coherence tomography, Humphrey visual fields (mean decibels and area with 1-log unit depression), and color vision. Treatment effect in this clinical proof of principle study was assessed by comparison of the prospective open-label treatment group with historical controls.Results: Of 5 subjects treated with EPI-743, 4 demonstrated arrest of disease progression and reversal of visual loss. Two patients exhibited a total recovery of visual acuity. No drug-related adverse events were recorded.Conclusions: In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in all but 1 of the 5 consecutively treated patients with LHON. Given the known natural history of acute and rapid progression of LHON resulting in chronic and persistent bilateral blindness, these data suggest that the previously described irreversible priming to retinal ganglion cell loss may be reversed. Arch Neurol. 2012; 69(3): 331-338
URI: http://repositorio.unifesp.br/11600/42649
ISSN: 0003-9942
Other Identifiers: http://dx.doi.org/10.1001/archneurol.2011.2972
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.